Search

Displaying results 5511 - 5520 of 10000 in total
  1. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma

  2. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  3. Drug

    Isopentane

    go.drugbank.com/drugs/DB16203
    Investigational

    Isopentane is under investigation in clinical trial NCT00752089 (Experimental Dentifrice Remineralization/fluoride Uptake in an in Situ Model).

  4. Drug

    Inecalcitol

    go.drugbank.com/drugs/DB04796
    Investigational

  5. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the most broadly used and effective cla...

  6. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders.

  7. Drug

    Cypermethrin

    go.drugbank.com/drugs/DB13721
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Cyfluthrin

    go.drugbank.com/drugs/DB13828
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Stevioside

    go.drugbank.com/drugs/DB16882
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.